Inhalation and Respiratory Drug Delivery

This study develops a deformable lung airway model to assess how airway deformation and carrier gas affect aerosol transport and deposition in the respiratory system.

This study demonstrates the use of a lung-on-chip model to study drug vehiculation via pulmonary surfactant, showing effective delivery and suppression of Mycobacterium tuberculosis.

This paper evaluates HFO-1234ze(E) as a low-GWP alternative to HFA-134a for reformulating a budesonide, glycopyrrolate, and formoterol fumarate pMDI, showing better stability and aerosol characteristics than HFA-152a.

This paper introduces a virtual NGI (vNGI) model using CFPD to predict APSD of inhaled drugs, validated against experimental data and aligned with NAMs for inhaler evaluation.

This paper develops a machine learning framework informed by computational fluid dynamics to optimize inhaler nozzle design for uniform drug delivery to small airways.

This paper models drug delivery in the lungs under varying breathing conditions, showing COPD patients have different drug deposition patterns compared to healthy individuals.

This paper develops enzyme-responsive condensates for inhaled delivery of biomacromolecules, enabling controlled release and targeted cell regulation.

This study observes a mosaic pattern of aerosol distribution in alveoli across species and ages, revealing functional heterogeneity in lung deposition and its implications for disease and therapy.

This paper shows aerosolized apolipoprotein A1 nanoparticles synthesized by microfluidics cross the lung barrier and reduce inflammation without causing toxicity or immunogenicity.

This paper presents open-source 3D printed manifolds for uniform airborne exposure of airway epithelial cells in vitro, showing reduced variation in aerosol deposition and functional responses to cannabis and tobacco smoke.

This study evaluates nebulized flagellin as a therapeutic for antibiotic-resistant pneumococcal pneumonia, showing it enhances immune response and synergizes with amoxicillin in mice.

The paper explores the use of inhalation-delivered RNA aptamers as a therapeutic approach against SARS-CoV-2.